Seizure drug levetiracetam shows potential to prevent Alzheimer's by halting toxic protein buildup
Northwestern University researchers report that the anti-seizure drug levetiracetam blocked the production of amyloid-beta 42 in animal models, cultured human neurons, and post-mortem Down syndrome brain tissue, suggesting a possible Alzheimer’s prevention mechanism by stopping toxic protein formation. The findings are preclinical and observational with no human trials yet, and experts caution that any preventive use would require very early treatment and consideration of side effects, while researchers pursue longer-lasting versions and plans for human testing.